Company / Shareholders' Equity
Aclaris Therapeutics, Inc. Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$103.1M
FY2025
5-year range
$103.1M / $197.6M
FY2021-FY2025
Trend
-34.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $198M to $103M over the past 2 years.
Based on SEC 10-K filings.
$103M in FY2025 with a 5-year CAGR of -13.7%.
Declined from $198M to $103M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -19.5%
- 5-Year CAGR
- -13.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -13.7%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 34.4% year-over-year.
- Peak shareholders' equity was recorded in FY2019.
- Lowest shareholders' equity in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $103.1M | -34.4% |
| FY2024 | $157.2M | -20.5% |
| FY2023 | $197.6M | +0.0% |
| FY2022 | $197.6M | +0.1% |
| FY2021 | $197.3M | -8.3% |
| FY2020 | $215.1M | -4.5% |
| FY2019 | $225.3M | +4.7% |
| FY2018 | $215.1M | +132.5% |
| FY2017 | $92.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026